These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
189 related items for PubMed ID: 23257406
21. Mycophenolate mofetil in the treatment of systemic lupus erythematosus. Dall'Era M. Curr Opin Rheumatol; 2011 Sep; 23(5):454-8. PubMed ID: 21720247 [Abstract] [Full Text] [Related]
22. Mycophenolate mofetil as maintenance therapy for childhood-onset systemic lupus erythematosus patients with severe lupus nephritis. Kizawa T, Nozawa T, Kikuchi M, Nagahama K, Okudela K, Miyamae T, Imagawa T, Nakamura T, Mori M, Yokota S, Tsutsumi H. Mod Rheumatol; 2015 Mar; 25(2):210-4. PubMed ID: 25159157 [Abstract] [Full Text] [Related]
23. Does mycophenolate mofetil prevent extra-renal flares in systemic lupus erythematosus? Results from an observational study of patients in a single practice treated for up to 5 years. Posalski JD, Ishimori Ml, Wallace DJ, Weisman MH. Lupus; 2009 May; 18(6):516-21. PubMed ID: 19395453 [Abstract] [Full Text] [Related]
24. Mycophenolate mofetil as a maintenance therapy for lupus-related diffuse alveolar hemorrhage: a case report. Al Rashidi A, Alajmi M, Hegazi MO. Lupus; 2011 Dec; 20(14):1551-3. PubMed ID: 21828160 [Abstract] [Full Text] [Related]
25. A national survey on current use of mycophenolate mofetil for childhood-onset systemic lupus erythematosus in Japan. Hara R, Miyazawa H, Nishimura K, Momoi T, Nozawa T, Kikuchi M, Sakurai N, Kizawa T, Shimamura S, Yasuda S, Hiromura K, Sada KE, Kawaguchi Y, Tamura N, Takei S, Takasaki Y, Atsumi T, Mori M. Mod Rheumatol; 2015 Dec; 25(6):858-64. PubMed ID: 26215483 [Abstract] [Full Text] [Related]
26. T-cell-mediated pure red-cell aplasia in systemic lupus erythematosus: response to cyclosporin A and mycophenolate mofetil. Arcasoy MO, Chao NJ. Am J Hematol; 2005 Feb; 78(2):161-3. PubMed ID: 15682416 [No Abstract] [Full Text] [Related]
27. Mycophenolate mofetil in low doses stabilizes and improves antineutrophil cytoplasmic antibody-associated vasculitis and lupus nephritis. Kazderova M, Jancova E, Rysava R, Merta M, Tesar V. Arch Med Res; 2008 Jan; 39(1):115-9. PubMed ID: 18068004 [Abstract] [Full Text] [Related]
28. Successful treatment of refractory thrombocytopenia with mycophenolate mofetil in a patient with systemic lupus erythematosus. Chang HK. J Korean Med Sci; 2005 Oct; 20(5):883-5. PubMed ID: 16224167 [Abstract] [Full Text] [Related]
29. [Manifestation of diffuse proliferative lupus nephritis in a patient treated with long-term mycophenolate mofetil]. Sixdorf U, Bauer H, Märker-Hermann E. Dtsch Med Wochenschr; 2006 Oct 13; 131(41):2266-9. PubMed ID: 17036267 [Abstract] [Full Text] [Related]
30. Mycophenolate mofetil is effective in reducing disease flares in systemic lupus erythematosus patients: a retrospective study. Nannini C, Crowson CS, Matteson EL, Moder KG. Lupus; 2009 Apr 13; 18(5):394-9. PubMed ID: 19318390 [Abstract] [Full Text] [Related]
31. Acute inflammatory syndrome following introduction of mycophenolate mofetil in a patient with systemic lupus erythematosus. Konon I, Cronin ME, Ryan LM. Arthritis Rheum; 2008 May 15; 59(5):754-6. PubMed ID: 18438909 [No Abstract] [Full Text] [Related]
32. Successful treatment of severe refractory lupus hepatitis with mycophenolate mofetil. Tagawa Y, Saito T, Takada K, Kawahata K, Kohsaka H. Lupus; 2016 Apr 15; 25(5):543-6. PubMed ID: 26762472 [Abstract] [Full Text] [Related]
33. Therapeutic drug monitoring of mycophenolate mofetil and enteric-coated mycophenolate sodium in patients with systemic lupus erythematosus. Djabarouti S, Duffau P, Lazaro E, Chapouly C, Greib C, Viallard JF, Pellegrin JL, Saux MC, Breilh D. Expert Opin Pharmacother; 2010 Apr 15; 11(5):689-99. PubMed ID: 20210680 [Abstract] [Full Text] [Related]
34. The Effect of Mycophenolate Mofetil on Non-Renal Manifestations in Systemic Lupus Erythematosus: Results from Korean Lupus Network Registry. Jung UH, Kwak SG, Choe JY, Lee SS, Kim SK. J Korean Med Sci; 2019 Jul 15; 34(27):e185. PubMed ID: 31293110 [Abstract] [Full Text] [Related]
35. [Statement on the use of mycophenolate mofetil for systemic lupus erythematosus]. Aringer M, Fischer-Betz R, Hiepe F, Kommission Pharmakotherapie der DGRh, Germany Society of Rheumatology. Z Rheumatol; 2013 Aug 15; 72(6):575-80. PubMed ID: 23756593 [Abstract] [Full Text] [Related]
36. Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil. Zahr N, Arnaud L, Marquet P, Haroche J, Costedoat-Chalumeau N, Hulot JS, Funck-Brentano C, Piette JC, Amoura Z. Arthritis Rheum; 2010 Jul 15; 62(7):2047-54. PubMed ID: 20506558 [Abstract] [Full Text] [Related]
38. Acquired pure red cell aplasia--a case report. Rahman J, Rashid MA, Yunus AB, Chowdhury SA, Kabir A, Khan MA, Wajed J. Bangladesh Med Res Counc Bull; 1998 Dec 15; 24(3):79-81. PubMed ID: 10874372 [Abstract] [Full Text] [Related]
39. Effective plasma concentrations of mycophenolic acid and its glucuronide in systemic lupus erythematosus patients in the remission-maintenance phase. Mino Y, Naito T, Shimoyama K, Ogawa N, Kawakami J. J Clin Pharm Ther; 2012 Apr 15; 37(2):217-20. PubMed ID: 21517926 [Abstract] [Full Text] [Related]
40. Mycophenolate mofetil in patients with systemic lupus erythematosus: a prospective pharmacokinetic study. Roland M, Barbet C, Paintaud G, Magdelaine-Beuzelin C, Diot E, Halimi JM, Lebranchu Y, Nivet H, Büchler M. Lupus; 2009 Apr 15; 18(5):441-7. PubMed ID: 19318398 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]